Announced
Completed
Financials
Tags
Minority
Private
Private Equity
Completed
Friendly
Single Bidder
United States
pioneering oncology treatment
Biotechnology
Acquisition
Venture Capital
Cross Border
Synopsis
Deep Track Capital, an investment firm focused exclusively on the life sciences industry, and Forbion, a venture capital firm, led a $175m Series B round in Mariana Oncology, a biotechnology research company focused on pioneering oncology treatment, with participation from Atlas Venture, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital and Eli Lilly & Company. "The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential. In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules. The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing,” said Simon Read, Mariana Oncology Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.